Frazier Life Sciences Management, L.P. Erasca, Inc. Transaction History
Frazier Life Sciences Management, L.P.
- $1.59 Billion
- Q1 2025
A detailed history of Frazier Life Sciences Management, L.P. transactions in Erasca, Inc. stock. As of the latest transaction made, Frazier Life Sciences Management, L.P. holds 22,575,851 shares of ERAS stock, worth $33.6 Million. This represents 1.95% of its overall portfolio holdings.
Number of Shares
22,575,851
Previous 19,391,687
16.42%
Holding current value
$33.6 Million
Previous $48.7 Million
36.46%
% of portfolio
1.95%
Previous 2.92%
Shares
3 transactions
Others Institutions Holding ERAS
# of Institutions
164Shares Held
222MCall Options Held
20.6KPut Options Held
5.7K-
T. Rowe Price Investment Management, Inc. Baltimore, MD17.3MShares$25.8 Million0.02% of portfolio
-
Vr Adviser, LLC New York, NY16.2MShares$24.2 Million5.36% of portfolio
-
Logos Global Management LP San Francisco, CA13MShares$19.4 Million3.47% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.7MShares$19 Million0.0% of portfolio
-
Suvretta Capital Management, LLC New York, NY12.3MShares$18.3 Million0.74% of portfolio
About Erasca, Inc.
- Ticker ERAS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 122,147,000
- Market Cap $182M
- Description
- Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...